Arvin AM - Search Results

1

A perspective on potential antibody-dependent enhancement of SARS-CoV-2.

Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW. Arvin AM, et al. Nature. 2020 Aug;584(7821):353-363. doi: 10.1038/s41586-020-2538-8. Epub 2020 Jul 13. Nature. 2020. PMID: 32659783

2

After the pandemic: perspectives on the future trajectory of COVID-19.

Telenti A, Arvin A, Corey L, Corti D, Diamond MS, García-Sastre A, Garry RF, Holmes EC, Pang PS, Virgin HW. Telenti A, et al. Nature. 2021 Aug;596(7873):495-504. doi: 10.1038/s41586-021-03792-w. Epub 2021 Jul 8. Nature. 2021. PMID: 34237771 Review.

3

Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines.

Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. Sasaki S, et al. Among authors: arvin am. J Virol. 2007 Jan;81(1):215-28. doi: 10.1128/JVI.01957-06. Epub 2006 Oct 18. J Virol. 2007. PMID: 17050593 Free PMC article. Clinical Trial.

4

Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.

Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, Beeler J, Arvin AM. Gans HA, et al. Among authors: arvin am. J Infect Dis. 2013 Feb 15;207(4):574-82. doi: 10.1093/infdis/jis719. Epub 2013 Jan 8. J Infect Dis. 2013. PMID: 23300162 Free PMC article.

5

Molecular mechanisms of varicella zoster virus pathogenesis.

Zerboni L, Sen N, Oliver SL, Arvin AM. Zerboni L, et al. Among authors: arvin am. Nat Rev Microbiol. 2014 Mar;12(3):197-210. doi: 10.1038/nrmicro3215. Epub 2014 Feb 10. Nat Rev Microbiol. 2014. PMID: 24509782 Free PMC article. Review.

6

A glycoprotein B-neutralizing antibody structure at 2.8 Å uncovers a critical domain for herpesvirus fusion initiation.

Oliver SL, Xing Y, Chen DH, Roh SH, Pintilie GD, Bushnell DA, Sommer MH, Yang E, Carfi A, Chiu W, Arvin AM. Oliver SL, et al. Among authors: arvin am. Nat Commun. 2020 Aug 18;11(1):4141. doi: 10.1038/s41467-020-17911-0. Nat Commun. 2020. PMID: 32811830 Free PMC article.

7

Prospects for a safe COVID-19 vaccine.

Haynes BF, Corey L, Fernandes P, Gilbert PB, Hotez PJ, Rao S, Santos MR, Schuitemaker H, Watson M, Arvin A. Haynes BF, et al. Sci Transl Med. 2020 Nov 4;12(568):eabe0948. doi: 10.1126/scitranslmed.abe0948. Epub 2020 Oct 19. Sci Transl Med. 2020. PMID: 33077678 Review.

8

Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine.

Arvin AM, Moffat JF, Redman R. Arvin AM, et al. Adv Virus Res. 1996;46:263-309. doi: 10.1016/s0065-3527(08)60074-3. Adv Virus Res. 1996. PMID: 8824702 Review.

9

Live attenuated varicella vaccine.

Arvin AM. Arvin AM. Pediatr Ann. 1997 Jun;26(6):384-8. doi: 10.3928/0090-4481-19970601-10. Pediatr Ann. 1997. PMID: 9188131 Free article. No abstract available.

10

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R; National Vaccine Advisory Committee. Arvin AM, et al. Clin Infect Dis. 2004 Jul 15;39(2):233-9. doi: 10.1086/421999. Epub 2004 Jun 25. Clin Infect Dis. 2004. PMID: 15307033 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

404 results

Search Page